Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit In High-Risk Relapsed Or Refractory Acute Myeloid Leukemia Patients With TP53 Mutations Accepted For Oral Presentation At The European Bone Marrow Transplant Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Actinium Pharmaceuticals, Inc. (ATNM) announced that the Phase 3 SIERRA trial results of Iomab-B for high-risk relapsed or refractory acute myeloid leukemia (r/r AML) patients with TP53 mutations have been accepted for oral presentation at the EBMT Annual Meeting. The trial showed Iomab-B significantly improved access to bone marrow transplants (BMT) and achieved durable Complete Remission (dCR) with high statistical significance, particularly in patients with TP53 mutations.
April 01, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Actinium Pharmaceuticals' Iomab-B shows significant promise in treating high-risk r/r AML patients with TP53 mutations, demonstrating 100% BMT access and achieving the primary endpoint of dCR with high statistical significance.
The positive results from the Phase 3 SIERRA trial, particularly the high statistical significance in achieving dCR and the 100% success rate in BMT access for patients treated with Iomab-B, are likely to be viewed favorably by investors and could lead to increased interest and investment in Actinium Pharmaceuticals. The acceptance of these results for presentation at a prestigious conference like the EBMT Annual Meeting further validates the potential of Iomab-B, potentially impacting ATNM's stock positively in the short term.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100